Shares of MediWound Ltd. (NASDAQ:MDWD) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $12.00.

A number of equities research analysts recently issued reports on MDWD shares. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Aegis reissued a “buy” rating and issued a $11.00 price target on shares of MediWound in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $10.00 price target on shares of MediWound and gave the company a “buy” rating in a research note on Monday, May 8th. Finally, Zacks Investment Research cut shares of MediWound from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th.

A number of hedge funds and other institutional investors have recently made changes to their positions in MDWD. Renaissance Technologies LLC raised its position in shares of MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the last quarter. Institutional investors own 27.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/21/mediwound-ltd-mdwd-receives-consensus-rating-of-buy-from-analysts.html.

Shares of MediWound (NASDAQ MDWD) traded up 0.69% during trading on Friday, reaching $7.30. 3,625 shares of the company’s stock traded hands. The company has a 50 day moving average price of $6.89 and a 200-day moving average price of $6.30. MediWound has a one year low of $4.25 and a one year high of $8.58. The stock’s market cap is $160.09 million.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.03. MediWound had a negative return on equity of 225.97% and a negative net margin of 1,053.25%. The firm had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.56 million. During the same period in the previous year, the business earned ($0.17) EPS. MediWound’s revenue for the quarter was up 112.6% compared to the same quarter last year. On average, equities research analysts expect that MediWound will post ($0.80) EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.